This 2019 expert opinion by Paley synthesizes the pathobiology, pathomechanics, and outcomes of congenital pseudarthrosis of the tibia. It introduces the Paley Classification and provides the biomechanical rationale for intentional tibio-fibular cross-union combined with zoledronic acid and BMP-2. The central question: why does every established technique fail half the time, and what anatomic and biological strategy can break that ceiling?
A child with anterolateral tibial bowing — fractured or not. Has a coin-flip chance of permanent union with any conventional technique. That 50% ceiling persists across intramedullary rodding, Ilizarov, combined fixation, and free vascularized fibula, confirmed across hundreds of patients in independent meta-analyses.
The cross-union concept changes the operation fundamentally. The goal is no longer end-to-end tibial repair. It is creation of a tibia-fibula bony bridge that doubles the cross-sectional area at the union site, converting a structurally fragile single-column repair into a two-bar linkage that is mechanically resistant to refracture.
When planning surgery, address all three primary problems simultaneously: straighten the anterolateral bow, achieve tibio-fibular cross-union with intramedullary support of both bones, and reduce proximal fibular migration. Giving zoledronic acid two weeks preoperatively protects the iliac cancellous graft from resorption. BMP-2 directly targets the deficient osteogenic signaling in the diseased periosteum.
Avoid any construct that requires the intramedullary rod to cross the ankle. The functional cost is a 68% loss of push-off strength, and the Fassier-Duval telescopic nail eliminates that tradeoff. These results are preliminary (mean follow-up 3.5 years, most patients not yet skeletally mature), but the biomechanical rationale is sound and the early data is the strongest published for any CPT technique.
This 2019 expert opinion by Paley synthesizes the pathobiology, pathomechanics, and outcomes of congenital pseudarthrosis of the tibia. It introduces the Paley Classification and provides the biomechanical rationale for intentional tibio-fibular cross-union combined with zoledronic acid and BMP-2. The central question: why does every established technique fail half the time, and what anatomic and biological strategy can break that ceiling?
A child with anterolateral tibial bowing — fractured or not. Has a coin-flip chance of permanent union with any conventional technique. That 50% ceiling persists across intramedullary rodding, Ilizarov, combined fixation, and free vascularized fibula, confirmed across hundreds of patients in independent meta-analyses.
The cross-union concept changes the operation fundamentally. The goal is no longer end-to-end tibial repair. It is creation of a tibia-fibula bony bridge that doubles the cross-sectional area at the union site, converting a structurally fragile single-column repair into a two-bar linkage that is mechanically resistant to refracture.
When planning surgery, address all three primary problems simultaneously: straighten the anterolateral bow, achieve tibio-fibular cross-union with intramedullary support of both bones, and reduce proximal fibular migration. Giving zoledronic acid two weeks preoperatively protects the iliac cancellous graft from resorption. BMP-2 directly targets the deficient osteogenic signaling in the diseased periosteum.
Avoid any construct that requires the intramedullary rod to cross the ankle. The functional cost is a 68% loss of push-off strength, and the Fassier-Duval telescopic nail eliminates that tradeoff. These results are preliminary (mean follow-up 3.5 years, most patients not yet skeletally mature), but the biomechanical rationale is sound and the early data is the strongest published for any CPT technique.